Drug Profile
MT 3724
Alternative Names: MT-3724Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Molecular Templates
- Developer Banner MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Molecular Templates; University of Arizona; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Bacterial toxins; Drug conjugates; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 16 Jun 2021 Molecular Templates terminates a phase II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV), due to sponsor's decision (NCT03488251)
- 16 Jun 2021 Molecular Templates terminates phase II trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA due to sponsor's decision (IV) (NCT03645395)
- 05 Apr 2021 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in Georgia, Moldova, Canada, Ukraine, Belarus, Poland, Spain (IV)